Barrett's esophagus: chemoprevention
Gastrointestinal Endoscopy Clinics of North America, ISSN: 1052-5157, Vol: 13, Issue: 3, Page: 419-432
2003
- 11Citations
- 11Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations11
- Citation Indexes11
- 11
- CrossRef6
- Captures11
- Readers11
- 11
Review Description
The clinical applicability of the experimental data discussed previously remains questionable, and results of clinical studies on chemoprevention in Barrett's esophagus are needed. The utility of selectively targeting acid exposure, ODC, and COX-2 is not clear, and elucidation of that role will be facilitated by a better understanding of the contribution of these factors in the development of Barrett's cancers. The insights already gained into the basic mechanisms of acid exposure, ODC, and COX-2 in the pathogenesis of Barrett's esophagus and esophageal adenocarcinoma hold promise for the development of future therapies aimed at these molecular targets and their signaling pathways. In preclinical studies, the ability of COX-2 selective NSAIDs and DFMO to inhibit carcinogenesis is encouraging. Results of well-designed, prospective clinical studies, however, are still needed to establish the efficacy of potent acid suppression, COX-2 inhibitors, and DFMO in the prevention of this malignancy.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1052515703000394; http://dx.doi.org/10.1016/s1052-5157(03)00039-4; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0042817870&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/14629099; http://linkinghub.elsevier.com/retrieve/pii/S1052515703000394; http://api.elsevier.com/content/article/PII:S1052515703000394?httpAccept=text/xml; http://api.elsevier.com/content/article/PII:S1052515703000394?httpAccept=text/plain; https://linkinghub.elsevier.com/retrieve/pii/S1052515703000394; http://dx.doi.org/10.1016/s1052-5157%2803%2900039-4; https://dx.doi.org/10.1016/s1052-5157%2803%2900039-4
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know